Skip to main content
Clinical Trials/NCT03395067
NCT03395067
Unknown
Not Applicable

Multidisciplinary Treatment of Obesity Prior to In Vitro Fertilization: Impact on Global Reproductive Outcomes

Hospital Clinic of Barcelona1 site in 1 country104 target enrollmentJanuary 28, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity
Sponsor
Hospital Clinic of Barcelona
Enrollment
104
Locations
1
Primary Endpoint
live birth rate of a healthy baby in a non-complicated pregnancy
Last Updated
8 years ago

Overview

Brief Summary

The aim of the present study is to evaluate the impact of a multidisciplinary treatment of obesity prior to IVF on global reproductive outcomes and maternofetal metabolic and cardiovascular risk factors.

This is a randomized controlled trial in obese infertile women before starting an IVF cycle. The intervention is based on a structured multidisciplinary program in support groups, which includes diet, physical activity and psychological therapy. IVF will be started immediately after this therapy. Patients included in the control group will start an IVF cycle immediately after the randomization. The results of this study may allow the identification of patients who would benefit from obesity treatment, so as to establish appropriate preventive and therapeutic strategies and to reduce the maternal obesity impact in future generations.

Detailed Description

The aim of the present study is to evaluate the impact of a multidisciplinary treatment of obesity prior to IVF on global reproductive outcomes and maternofetal metabolic and cardiovascular risk factors. This is a randomized controlled trial in obese infertile women (body mass index ≥30 kg/m2) before starting an IVF cycle. In the intervention group, the aim is a weight loss of at least 10% in a 16-week period of treatment based on a multidisciplinary approach and support groups, which includes diet, physical activity and psychological therapy. IVF will be started immediately after this period. Patients included in the control group will start an IVF cycle immediately after the randomization. The results of this study may allow the identification of patients who would benefit from obesity treatment, so as to establish appropriate preventive and therapeutic strategies and to reduce the maternal obesity impact in future generations.

Registry
clinicaltrials.gov
Start Date
January 28, 2018
End Date
December 2020
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gemma Casals i Soler

Principal Investigator

Hospital Clinic of Barcelona

Eligibility Criteria

Inclusion Criteria

  • Obese infertile patients (body mass index ≥ 30 Kg/m2) prior to an in vitro fertilization cycle

Exclusion Criteria

  • Pathological conditions: diabetes type I, Cushing syndrome, premature ovarian failure, uncontrolled thyroidal dysfunction, hepatic and/or renal dysfunction, antiphospholipid syndrome, medical condition that contraindicate ovarian stimulation and/or pregnancy
  • Simultaneous practice of another strategy to lose weight
  • Physical conditions limiting exercise training
  • Patients unable to understand spanish language or to give informed consent

Outcomes

Primary Outcomes

live birth rate of a healthy baby in a non-complicated pregnancy

Time Frame: 10 months after starting the IVF treatment

live birth rate in a pregnancy without major complications: gestational diabetes, hypertensive disorders, preterm delivery, congenital anomalies, stillbirth, neonatal death, shoulder dystocia, maternal venous thromboembolism, fetal growth abnormal outcomes (macrosomia, large for gestational age, intrauterine growth restriction)

Secondary Outcomes

  • IVF outcomes: number of oocytes(3 months after starting IVF cycle)
  • IVF outcomes: number of embryos(3 months after starting IVF cycle)
  • postpartum anthropometric outcomes: neonatal height (centimeters)(12 months after the delivery)
  • hormonal parameters: insulin(2 years (simultaneous analysis of all the biological samples))
  • hormonal parameters: adiponectin(2 years (simultaneous analysis of all the biological samples))
  • postpartum anthropometric outcomes: neonatal weight (grams)(12 months after the delivery)
  • postpartum anthropometric outcomes: neonatal skin fold measurements (millimeters)(12 months after the delivery)
  • postpartum anthropometric outcomes: maternal weight (kilograms)(12 months after the delivery)
  • anthropometric parameters: abdominal circumference (centimeters)(4 months after starting the intervention)
  • IVF outcomes: cycle cancellation rate(3 months after starting IVF cycle)
  • IVF outcomes: number of good quality embryos(3 months after starting IVF cycle)
  • IVF outcomes: clinical pregnancy rate(3 months after starting IVF cycle)
  • fetal ultrasound(26-30 weeks after confirmation of pregnancy)
  • anthropometric parameters: weight (kilograms)(4 months after starting the intervention)
  • hormonal parameters: antimullerian hormone (AMH)(2 years (simultaneous analysis of all the biological samples))
  • hormonal parameters: leptin(2 years (simultaneous analysis of all the biological samples))
  • hormonal parameters: ghrelin(2 years (simultaneous analysis of all the biological samples))
  • IVF outcomes: gonadotropin doses (UI)(3 months after starting IVF cycle)
  • postpartum anthropometric outcomes: maternal abdominal circumference (centimeters)(12 months after the delivery)
  • anthropometric parameters: body mass index - BMI (kilograms/metro2)(4 months after starting the intervention)
  • IVF outcomes: miscarriage rate(3 months after starting IVF cycle)

Study Sites (1)

Loading locations...

Similar Trials